ABOUT 4BASEBIO
4basebio is revolutionizing DNA manufacturing
Based in the heart of the Cambridge UK biotech ecosystem, we are pioneering a paradigm shift: the transition from legacy bacterial-based manufacturing to high-performance, synthetic enzymatic DNA synthesis. Our mission is to empower pharma and biotech innovators with synthetic, cell-free DNA that eliminates risks and streamlines the path from preclinical development to commercialization.
Our scientific advantage
At 4basebio, we don’t just manufacture DNA; we engineer it for the future. Our proprietary enzymatic synthesis platform bypasses the "bottleneck" of traditional DNA manufacturing. By moving away from traditional cell-based, bacterial-fermentation systems, we offer a unique approach to critical starting material. The advantages of synthetic DNA are as follows:
- Unrivaled purity: We eliminate the risks of bacterial contaminants and antibiotic-resistance genes, ensuring a safer profile for clinical applications.
- Scalability at speed: Our enzymatic process transforms timelines, moving from design to GMP-grade DNA and mRNA in a fraction of the time required by pDNA.
- Precision engineering: We create application-specific DNA constructs tailored for the precise needs of gene editing (CRISPR), mRNA production, viral vector, and DNA vaccines.
INDUSTRY INSIGHTS
-
![cmo-cdmo-drug-discovery-GettyImages-184944030 (1)]( "The Switch To Cell-Free DNA: Strategic And Regulatory Considerations")
Learn how risk-based studies, quality attributes, and proactive regulatory engagement support confident manufacturing transitions.
-
![GettyImages-1409734937-3d-rendering-rna-dna]( "Current Challenges In The Plasmid DNA Manufacturing Process")
PolyA tail stability shapes mRNA potency, consistency, and manufacturability. Addressing integrity early reduces variability, simplifies workflows, and supports reliable clinical scale‑out.
-
![GettyImages-2217414221 manufacturing, tablet]( "The Switch To Cell-Free DNA: Streamlining Advanced Therapy Manufacturing")
Cell‑free DNA manufacturing removes bacterial risk and complexity, enabling faster, flexible production that supports advanced and personalized therapies with consistent quality and regulatory confidence.
-
![cancer-treatment-clinical-trials-GettyImages-1605434136]( "Redefining Biomanufacturing For Personalized Cancer Vaccines")
Personalized cancer vaccines need fast, flexible manufacturing. Cell‑free synthetic DNA enables rapid, small‑batch mRNA production, supporting individualized therapies beyond plasmid‑based limits.
-
![cell-gene-therapy-GettyImages-2157300524]( "Safe, Scalable And GMP-Ready DNA")
Cell‑free synthetic DNA provides a scalable, safer alternative to plasmids by eliminating bacterial risks, simplifying quality control, and enabling complex sequences under GMP‑aligned conditions.
CONTACT INFORMATION
4basebio
25 Norman Way, Over
Cambridge, CB24 5QE
UNITED KINGDOM
Contact: Florent Foxdoxel, Inside Sales Manager
SOLUTIONS
-
![GettyImages-1453953422 RNA]( "Simplify Your mRNA Workflow From The Start")
Cell‑free DNA simplifies mRNA production by removing bacterial risk, stabilizing polyA tails, and eliminating extra steps — delivering higher yields and cleaner workflows.
